About us

Founded in 1986 by two former employees of Abbott France, Theradiag has been dedicated, at first, to distributing in vitro diagnostics, specifically for autoimmune diseases. The main stages of Theradiag’s development are the following:

2012

IPO of the company on NYSE Alternext on December 11th, 2012.

BMD becomes Theradiag.

2011

Patent filing for the monitoring of the treatment of autoimmune diseases by anti-TNFα, through multiple bio markers.

2010

Appointment of Michel Finance as Theradiag’s Chief Executive Officer.

2010

Launch by Theradiag in France, as part of an exclusive partnership, of two genetic and oncogenetic products supplied by the U.S. company Asuragen, expert in molecular biology and microARN technology.

2010

CE marking of the first Lisa-Tracker kit to monitor the treatment of autoimmune diseases by anti-TNFα.

2008

First financial support by OSEO Innovation, through a reimbursable fund of €550,000, for the development of a multi-parametric monitoring system for treatment of autoimmune diseases by anti-TNFα.
Initial growth of the Company in theranostics under the strategic industrial innovation plan, TRACKER, carried out in partnership with the French biotech company Neovacs. As part of OSEO Innovation’s support, Theradiag has already received some €1.5 million (in subsidies and reimbursable advances), notably to develop a universal solution to monitor the treatment of autoimmune diseases.

2006

Awarded  “Innovative Company” for three years for its Innovation Mutual Funds (FCPI), by OSEO Innovation

2004

Commercial launch of FIDIS™, a line of autoimmune kits based on Luminex’s Multiplex technology and automated instruments.

2000

First fund-raising from venture capitalists to finance the Company’s growth.

2000

Expansion of its international distribution network by creating an export department and signing its first distribution partnerships.

1999

Signing of a development and sub-contracting agreement with the U.S. company Luminex to allow Theradiag to use Multiplex technology to develop an in house range of diagnostic materials and kits for autoimmune diseases diagnosis.

1992

Commercialization of the Company’s first in house products.

1990

Theradiag’s development into activities to complement research and development and production.